An Open Label Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria
Status: Completed
Location: See all (18) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
This phase 2a trial will evaluate the safety and efficacy of EVO756 in subjects with chronic inducible urticaria, including symptomatic dermographism and cold urticaria.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:
• Confirmed diagnosis of chronic inducible urticaria for at least 3 months.
• Positive response following provocation using the TempTest or FricTest at Screening and Day 1.
Locations
United States
Alabama
Cahaba Dermatology & Skin Health Center, LLC
Birmingham
California
California Allergy and Asthma Medical Group
Los Angeles
Integrative Skin Science and Research
Sacramento
West Dermatology Research Center
San Diego
Florida
Advanced Clinical Research Institute
Tampa
Georgia
Aeroallergy Research Laboratories of Savannah, Inc.
Savannah
Idaho
Treasure Valley Medical Research
Boise
Indiana
Dawes Fretzin Clinical Research Group, LLC
Indianapolis
Southern Indiana Clinical Trials
New Albany
Indiana Clinical Trials Center, P.C.
Plainfield
Louisiana
DelRicht Research
Baton Rouge
Maryland
Chesapeake Clinical Research, Inc
White Marsh
North Dakota
Red River Research Partners
Fargo
New York
OptiSkin Medical
New York
Ohio
Bexley Dermatology Research
Bexley
Oklahoma
Allergy, Asthma, and Clinical Research Center
Oklahoma City
Pennsylvania
Allergy and Clinical Immunology Associates
Pittsburgh
Texas
Austin Institute for Clinical Research
Pflugerville
Time Frame
Start Date: 2024-08-14
Completion Date: 2025-05-08
Participants
Target number of participants: 30
Treatments
Experimental: EVO756
Related Therapeutic Areas
Sponsors
Leads: Evommune, Inc.